A network for sharing data and resources in immuno-oncology
Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI
['FUNDING_OTHER'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-10872397
This study is all about finding better ways to use immune therapies to fight cancer by working together to understand why some cancers resist treatment and exploring new combinations of therapies, all aimed at helping adults with cancer feel better and live longer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-10872397 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the clinical use of immuno-oncology strategies by collaborating to understand cancer resistance mechanisms, discover new immune targets, and evaluate combination therapies. A multidisciplinary team will manage data collection and analysis to support various immuno-oncology projects aimed at treating and preventing cancers in adults. The initiative will streamline access to analytical expertise and foster collaboration among researchers to improve cancer treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with cancer who may benefit from innovative immunotherapy approaches.
Not a fit: Patients with non-malignant conditions or those who are not adults may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for cancer patients.
How similar studies have performed: Previous research in immuno-oncology has shown promising results, indicating that collaborative approaches can lead to significant advancements in cancer treatment.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HUTSON, ALAN DAVID — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: HUTSON, ALAN DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer